logo
logo
The Ensign Group, Inc.

The Ensign Group, Inc.

NASDAQ•ENSG
CEO: Mr. Christopher R. Christensen
セクター: Healthcare
業種: Medical - Care Facilities
上場日: 2007-11-09
The Ensign Group, Inc. provides skilled nursing, senior living, and rehabilitative services. It operates through two segments: Skilled Services and Standard Bearer. The company's Skilled Services segment engages in the operation of skilled nursing facilities and rehabilitation therapy services for patients with chronic conditions, prolonged illness, and the elderly; and offers nursing facilities including specialty care, such as on-site dialysis, ventilator care, cardiac, and pulmonary management, as well as standard services comprising room and board, special nutritional programs, social services, recreational activities, entertainment, and other services. Its Standard Bearer segment is comprised of selected real estate properties owned by Standard Bearer and leased to skilled nursing and senior living operators. In addition, the company provides ancillary services consisting of digital x-ray, ultrasound, electrocardiograms, sub-acute services, dialysis, respiratory, and long-term care pharmacy and patient transportation to people in their homes or at long-term care facilities, as well as mobile diagnostics. It operates in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. The company was incorporated in 1999 and is based in San Juan Capistrano, California.
連絡先情報
29222 Rancho Viejo Road, Suite 127, San Juan Capistrano, CA, 92675, United States
949-487-9500
ensigngroup.net
時価総額
$12.46B
PER (TTM)
35.9
33.4
配当利回り
0.1%
52週高値
$216.92
52週安値
$118.73
52週レンジ
97%
順位25Top 11.9%
5.6
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 5.6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$1.36B+0.00%
直近4四半期の推移

EPS

$1.66+0.00%
直近4四半期の推移

フリーCF

$133.48M+0.00%
直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Total Revenue Growth Strong Total revenue reached $5.06B USD, marking an 18.7% increase over prior year results, showing strong momentum.
Net Income Attributable Rises Net income attributable to Ensign grew to $344.0M USD, reflecting 15.4% growth compared to the previous period.
Same Facility Occupancy Improves Same Facility operational bed occupancy reached 82.9%, a 2.0 percentage point increase from 2024 performance metrics.
Skilled Mix Revenue Percentage Climbs Skilled mix revenue percentage climbed to 49.4% of total skilled revenue, up 0.8 percentage points year-over-year.

リスク要因

Reimbursement Rate Reductions Medicare and Medicaid rate changes, spending requirements, and evaluation standards pose material adverse effects on revenues.
Increased Labor Cost Competition Shortage of nurses and skilled personnel increases staffing labor costs, potentially leading to monetary fines under state laws.
Regulatory Scrutiny and Audits Subject to extensive government reviews, audits, and investigations, risking refunds, fines, and potential loss of licensure.
Litigation Exposure Remains High High risk of liability from patient claims, with increased damage caps in states like California potentially increasing costs.

見通し

Continued Acquisition Expansion Focus Plan to continue acquiring additional operations in existing and new markets, building on 46 new additions in 2025.
Grow Talent Base Development Primary growth strategy involves expanding talent base and developing future leaders through rigorous training programs.
Increase High Acuity Patient Mix Focus on increasing overall percentage mix of higher acuity patients to capture higher reimbursement rates effectively.
Real Estate Portfolio Growth Committed to growing the real estate portfolio, viewing owned properties as a key component for sustained earnings growth.

同業比較

売上高 (TTM)

Molina Healthcare, Inc.MOH
$45.43B
+11.7%
Universal Health Services, Inc.UHS
$16.99B
+10.2%
DaVita Inc.DVA
$13.64B
+6.5%

粗利益率 (最新四半期)

Universal Health Services, Inc.UHS
90.8%
+0.6pp
BioMarin Pharmaceutical Inc.BMRN
81.2%
+7.2pp
Align Technology, Inc.ALGN
65.3%
-5.5pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
UHS$15.09B11.019.9%33.3%
ALGN$13.19B32.110.4%1.3%
ENSG$12.46B35.916.6%76.1%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
5.1%
安定成長
4四半期純利益CAGR
5.9%
収益性の着実な向上
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年4月27日
|
EPS:-
|
売上高:-
財務レポート
財務データ
全年度
  • Form 10-K - FY 2025

    会計期末: 2025年12月31日|提出日: 2026年2月4日|
    売上高: $5.06B+18.7%
    |
    EPS: $6.00+14.1%
    予想を上回る
  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月3日|
    売上高: $1.30B+19.8%
    |
    EPS: $1.46+5.8%
    予想を下回る
  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年7月24日|
    売上高: $1.23B+18.5%
    |
    EPS: $1.48+17.5%
    予想を下回る
  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年4月29日|
    売上高: $1.17B+16.1%
    |
    EPS: $1.41+15.6%
    予想を下回る
  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月5日|
    売上高: $4.26B+14.2%
    |
    EPS: $5.26+39.9%
    予想を上回る
  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年10月24日|
    売上高: $1.08B+15.0%
    |
    EPS: $1.38+21.1%
    予想通り
  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年7月25日|
    売上高: $1.04B+12.5%
    |
    EPS: $1.26+9.6%
    予想を下回る
  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月1日|
    売上高: $1.01B+13.9%
    |
    EPS: $1.22+13.0%
    予想を下回る